Table 1 Intravenous C16 and Ang-1 enhanced the efficacy of PMSC therapy for restoring CSEP and CMEP latency and amplitude in rats with EAE.

Normal

11.6 ± 0.20**

(ES = 8.14, P = 0.003)

16.22 ± 0.24**

(ES = 6.59, P = 0.0027)

2.15 ± 0.36* (ES = 10.29, P = 0.011)

Vehicle

18.38 ± 0.89

25.32 ± 1.15

0.78 ± 0.06

PMSCs

13.44 ± 1.54**

(ES = 0.76, P = 0.004)

19.45 ± 0.85**

(ES = 2.87, P = 0.001)

2.34 ± 0.68* (ES = 3.35, P = 0.03)

P + C + A

12.08 ± 0.99**

(ES = 3.55, P = 0.0006; vs. PMSCs: ES = 0.4, P = 0.13)

17.31 ± 0.42**^&

ES = 5.34, P = 0.0001; vs. PMSCs: ES = 2.38, P = 0.009)

2.07 ± 0.33* (ES = 11.47, P = 0.0109; vs. PMSCs: ES = 0.47, P = 0.28)

3 weeks pi

Group

Normal

5.2 ± 0.14**

(ES = 9.09, P = 0.002)

Vehicle

13.24 ± 0.93

PMSCs

5.81 ± 0.22**

(ES = 8.13, P < 0.0001)

P + C + A

5.83 ± 0.34**

(ES = 7.55, P = 0.0001; vs. PMSCs: ES = 0.12, P = 0.46)

8 weeks pi

Groups

N

P

Wave amplitude (V_mean ± SD)

Normal

11.22 ± 0.94**

(ES = 2.53, P = 0.0002)

16.76 ± 1.08**

(ES = 3.34, P = 0.0001)

2.86 ± 0.33** (ES = 16.26, P = 0.005)

Vehicle

27.22 ± 2.33

32.98 ± 1.92

1.01 ± 0.07

PMSCs

16.85 ± 1.68**

(ES = 2.16, P = 0.0017)

22.41 ± 1.48**

(ES = 1.8, P = 0.0008)

2.69 ± 0.36** (ES = 12.49, P = 0.0078)

P + C + A

14.32 ± 1.35**

(ES = 1.77, P = 0.0006; vs. PMSCs: ES = 0.54, P = 0.06)

19.01 ± 1.78**^&

(ES = 2.04, P = 0.0004; vs. PMSCs: ES = 0.63, P = 0.03)

2.50 ± 0.14** (ES = 60.82, P < 0.0001; vs. PMSCs: ES = 1.27, P = 0.22)

8 weeks pi

Groups

Normal

5.32 ± 0.43**

(ES = 52.22, P < 0.0001)

Vehicle

17.28 ± 0.21

PMSCs

6.34 ± 0.88**

(ES = 13.37, P < 0.0001)

P + C + A

5.52 ± 1.45**

(ES = 5.48, P = 0.003; vs. PMSCs: ES = 0.29, P = 0.22)